SLC5A2 and diabetes mellitus: In adults with type 1 diabetes mellitus, Sotagliflozin, an SGLT-2 inhibitor, when used as an adjunct to insulin therapy, significantly reduced the predicted 5- and 10-year cardiovascular disease risk, possibly by reducing body weight and blood pressure [58].